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TO THE EDITORAdenosine-Dependent
Vasodilation and the
Quest for “Maximal”
Hyperemia
Does Flow Provide an Answer?With great interest, we read the work of Adjedj
and colleagues (1), demonstrating the dose-response
curve of intracoronary adenosine for hyperemia,
expressed in terms of coronary ﬂow velocity. The
authors should be congratulated for this elegant
study, which by focusing on the ﬂow response to
adenosine has important incremental value over
previous studies on the subject. Nonetheless, some
considerations may require further attention.
First, the authors studied unobstructed coronary
vessels only. Although, as explained by the authors,
only in these vessels an adequate dose–response
curve of adenosine for ﬂow velocity can be obtained,
it is important to realize that vasoreactivity in the
distal microvasculature is altered in the presence of
epicardial stenosis due to altered tone regulation
and remodeling of the microcirculation (2). Hence,
the present ﬁndings apply to unobstructed coronary
vessels and cannot be unequivocally extrapolated to
stenosed vessels. Nonetheless, the extrapolation
to the fractional ﬂow reserve (FFR) framework is
hypothesis-generating. Because the expected differ-
ence between the minimal and observed FFR is
smaller than the variability of the FFR measurement
itself for adenosine doses above 40 mg, the authors
document that low-dose adenosine administration
does not lead to relevant ambiguities in FFR assess-
ment. This ﬁnding importantly strengthens the con-
clusions derived from clinical studies that were
previously scrutinized for using low(er)-dose adeno-
sine administration (3,4).
Second, in contrast to many interventional prac-
tices, the authors decided not to ﬂush the dead space
after administration of adenosine, and estimate a 15%
difference in administered adenosine versus the
actual dose reaching the coronary ostium. However, a6-F guiding catheter as used by the authors has over
2 ml worth of dead space. With administration of the
documented dose of adenosine in 8 ml (1), a 2-ml dead
space means 25% of the administered dose will not
reach the coronary ostium: of the proposed 160- to
200-mg and 60- to 100-mg doses for the left coronary
artery and right coronary artery, respectively, only 120
to 150 mg and 45 to 75 mg reached the coronary ostium.
This does not invalidate the study results, but stresses
the notably low doses of intracoronary adenosine
required to exhaust adenosine-dependent vasodila-
tion, and suggests that the proposed doses should
not be ﬁrmly extrapolated to the clinical setting.
Finally, it is important to realize that neither this
study, nor most of the preceding studies using FFR
as the endpoint, assess the achievement of maximal
hyperemia. Despite using this terminology, all of
these studies merely investigate the amount of
adenosine required to exhaust adenosine-dependent
vasodilation. It is well-known that many vasocon-
strictors interfere with the complete abolishment
of vasomotor tone required to achieve “maximal”
hyperemia (5). The prevailing balance between
adenosine-dependent and non–adenosine-dependent
vasoconstriction determines at what dose and to what
extent adenosine is able to dilate the coronary resis-
tance vessels. This balance will be different in each
patient, which makes the identiﬁcation of a single
dose of adenosine to optimize adenosine-induced
vasodilation an impossible task.
Notwithstanding the aforementioned consider-
ations, the present study (1) is the ﬁrst to provide
adenosine dosing advice based on the vasodilatory
response of the unobstructed coronary circulation
to intracoronary adenosine. More importantly, rest
assured: it documents the appropriateness of in-
tracoronary adenosine administration for invasive
physiological assessment even at low doses of around
40 mg of adenosine.*Tim P. van de Hoef, MD, PhD
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OLIVE Registry, a
Prospective Multicenter
Study of Patients With
Critical Limb IschemiaWe read with much interest the recent paper and
editorial by Iida et al. (1) and Menard (2), respectively,
in JACC: Cardiovascular Interventions assessing the
mid-term outcomes after endovascular therapy in a
prospective multicenter (A Prospective, Multi-Center,
Three Year Follow-Up Study on Endovascular Treat-
ment for Infra-Inguinal Vessel in Patients With Critical
Limb Ischemia [OLIVE]) registry in 314 patients with
chronic limb ischemia (CLI). At 3 years, amputation-
free survival, freedom from major adverse limb
events, and wound-free survival rates were 55.2%,
84.0%, and 49.6%, respectively. Wound recurrence
rate was at 3 years was 43.9%. After multivariable
analysis, age (hazard ratio [HR]: 1.43, p ¼ 0.001), body
mass index 18.5 (HR: 2.17, p ¼ 0.001), dialysis (HR:
2.91, p < 0.001), and Rutherford 6 (HR: 1.64, p ¼ 0.047)
were identiﬁed as predictors of 3-year major ampu-
tation or death. Statin use (HR: 0.28, p ¼ 0.02),
Rutherford 6 (HR: 2.40, p ¼ 0.02), straight-line ﬂow to
the foot (HR: 0.27, p ¼ 0.001), and heart failure
(HR: 1.96, p ¼ 0.04) were identiﬁed as 3-year major
adverse limb event predictors. Finally, CLI due
to isolated, below-the-knee lesion was a wound
recurrence predictor (HR: 4.28, p ¼ 0.001). Three-yearsurvival, freedom from major amputation, and
reintervention rates were 63.0%, 87.9%, and 43.2%,
respectively.
The authors should be commended for writing
this important and timely paper, especially as the
research in CLI has reoriented towards optimizing
long-term patient outcomes. Long-term patient out-
comes beyond limb salvage are critical because large
registry studies in peripheral artery disease have
shown that suboptimal medical management in-
creases the risk of cardiovascular death, stroke, and
myocardial infarction by up to 7-fold at 3 years (3). In
this regard, it is striking that in the OLIVE registry,
despite a very high incidence of established vascular
disease (100%) and cardiovascular disease (21% to
46%), only 26% are on statin therapy, 40% on clopi-
dogrel, and/or 50% on cliostazol. Additionally, there
are no data presented on whether the statin use or
blood pressure control had been optimized and
reached the targets set by the TransAtlantic Inter-
Society Consensus (TASC) II guidelines (4). However,
the authors should be congratulated for reporting
on the degree of optimal medical therapy in their
patient subset. In fact, most of the recent prospective
studies have focused primarily on endovascular de-
vice use/techniques to optimize limb outcomes
and have not quantiﬁed whether patients received
guideline-based optimal medical therapy before or
after endovascular intervention (1).
These observations suggest a persistent deﬁcit in
the quality of medical care in CLI and have profound
implications. First, population-based interventions
that improve medical therapy for CLI may have a
large impact both on amputation-free survival and
reducing the risk of cardiovascular mortality and
myocardial infarction. Second, the addition of an
optimal medical treatment metric in the assessment
of endovascular and/or surgical interventions on CLI
will allow for uniform comparisons between different
treatment strategies. Furthermore, it is known that
the costs of inpatient care in the year before amputa-
tion in patients with CLI is more than $20,000 per
patient. This cost varies by 2-fold across hospital
referral regions in the United States; much of this
difference in cost is driven by the use of revasculari-
zation treatments and not related to patient or
amputation care. Additionally, there is little evidence
that higher spending on vascular care (primarily
endovascular care) in the year prior lowers amputa-
tion rates. The quality of baseline medical therapy
will be important in assessing and comparing the
overall quality and cost of vascular care pro-
vided by institutions and individual providers (5).
This is axiomatic in light of the environment in
